The Application of Modified Targeted Nanoparticles in Tumor Diagnosis and Treatment
DOI:
https://doi.org/10.61173/r5are698Keywords:
-Tumor microenvironment (TME), Modified nanoparticles, Targeted positioning, Diagnosis and treat-ment techniquesAbstract
Nanoparticles (NPs) have been widely used in the field of oncology due to their characteristics such as non-invasiveness and targeting. Tumors are one of the major public health problems worldwide, and timely targeted diagnosis and treatment of tumors are particularly important. However, common nanoparticles have disadvantages such as insufficient targeting and poor adaptability to the tumor microenvironment (TME). TME can interact with tumors and jointly promote the tumor process. Moreover, at present, the single use of tumor diagnosis and treatment methods such as imaging techniques, surgery, photodynamic therapy (PDT) etc., may cause certain damage to the body, cannot conduct real-time monitoring, and lack targeting and other limitations. After being modified with specific materials, NPs can specifically target the TME based on the combined modifiers and can also integrate multiple modifiers to enhance the targeted positioning. The combination of the active targeting and non-invasive characteristics of NPs reduces the damage to normal tissues of the body. The combined application of nanotechnology with other diagnostic and therapeutic technologies can achieve real-time imaging detection at specific locations while conducting treatment, even achieve integrated diagnosis and treatment. This review explores the targeted effect of modified NPs on tumors and the application of NPs in combination with other diagnostic and therapeutic techniques.
References
[1] F. Bray, M. Laversanne, H. Sung, J. Ferlay, R. L. Siegel, I. Soerjomataram, and A. Jemal, “Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA Cancer J. Clin., vol. 74, pp. 229–263, 2024.
[2] L. Wang, C. Dai, L. Jiang, G. Tong, Y. Xiong, K. Khan, Z. Tang, X. Chen, and H. Zeng, “Advanced devices for tumor diagnosis and therapy,” Small, vol. 17, 2100003, 2021.
[3] A. C. Monteiro, A. P. Lepique, M. Bonamino, and M. B. Fuertes, “Editorial: Tumor microenvironment immunophenotypes and disease progression,” Front. Immunol., vol. 14, 2023.
[4] S. Akkın, G. Varan, and E. Bilensoy, “A review on cancer immunotherapy and applications of nanotechnology to chemoimmunotherapy of different cancers,” Molecules, vol. 26, 3382, 2021.
[5] Y. Zhang, Y. Wang, A. Zhu, N. Yu, J. Xia, and J. Li, “Dualtargeting biomimetic semiconducting polymer nanocomposites for amplified theranostics of bone metastasis,” Angew. Chem. Int. Ed., vol. 63, e202310252, 2024.
[6] M. Talelli, S. Oliveira, C. J. F. Rijcken, E. H. E. Pieters, Dean&Francis ISSN 2959-409X T. Etrych, K. Ulbrich, R. C. F. van Nostrum, G. Storm, W. E. Hennink, and T. Lammers, “Intrinsically active nanobodymodified polymeric micelles for tumor-targeted combination therapy,” Biomaterials, vol. 34, pp. 1255–1260, 2013.
[7] C. Dong, Q. Zhou, J. Xiang, F. Liu, Z. Zhou, and Y. Shen, “Self-assembly of oxidation-responsive polyethylene glycolpaclitaxel prodrug for cancer chemotherapy,” J. Control. Release, vol. 321, pp. 529–539, 2020.
[8] D. C. Paup, L. P. Coniglio, and L. G. Clemens, “Hormonal determinants in the development of masculine and feminine behavior in the female hamster,” Behav. Biol., vol. 10, pp. 353– 363, 1974.
[9] H. Vorherr, R. H. Messer, U. F. Vorherr, S. W. Jordan, and M. Kornfeld, “Teratogenesis and carcinogenesis in rat offspring after transplacental and transmammary exposure to diethylstilbestrol,” Biochem. Pharmacol., vol. 28, pp. 1865–1877, 1979.
[10] H. Haaf and M. Metzler, “Covalent binding of diethylstilbestrol to microsomal protein in vitro correlates with the organotropism of its carcinogenicity,” Carcinogenesis, vol. 6, pp. 659–660, 1985.
[11] L. Wang, Y. Zhang, G. Liu, C. Zhang, and S. Wang, “A time-resolved fluorescence immunoassay for the ultrasensitive determination of diethylstilbestrol based on the double-codified gold nanoparticles,” Steroids, vol. 89, pp. 41–46, 2014.
[12] S. Li, W. Mei, X. Wang, S. Jiang, X. Yan, S. Liu, and X. Yu, “Choline phosphate lipid insertion and rigidification of cell membranes for targeted cancer chemo-immunotherapy,” Chem. Commun., vol. 57, pp. 1372–1375, 2021.
[13] J. Peng, J. Zhou, R. Sun, Y. Chen, D. Pan, Q. Wang, Y. Chen, Z. Gong, and Q. Du, “Dual-targeting of artesunate and chloroquine to tumor cells and tumor-associated macrophages by a biomimetic PLGA nanoparticle for colorectal cancer treatment,” Int. J. Biol. Macromol., vol. 244, 125163, 2023.
[14] J. Niu, Y.-H. Liu, W. Xu, W.-W. Xu, Y.-H. Song, J. Yu, Y.-M. Zhang, and Y. Liu, “Morpholine-modified permethyl β-cyclodextrin supramolecular nanoparticles for precise dualtargeted imaging,” Chem. Commun., vol. 59, pp. 4680–4683, 2023.
[15] A. M. E. Abdalla, L. Xiao, M. W. Ullah, et al., “Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics,” Theranostics, vol. 8, no. 2, pp. 533–548, 2018.
[16] F. Wang, Y. Li, H. Jiang, C. Li, Z. Li, C. Qi, Z. Li, Z. Gao, B. Zhang, and J. Wu, “Dual-ligand-modified liposomes co-loaded with anti-angiogenic and chemotherapeutic drugs for inhibiting tumor angiogenesis and metastasis,” Int. J. Nanomedicine, vol. 16, pp. 4001–4016, 2021.
[17] T. Kagawa, Y. Matsumi, H. Aono, T. Ohara, H. Tazawa, K. Shigeyasu, S. Yano, S. Takeda, Y. Komatsu, R. M. Hoffman, T. Fujiwara, and H. Kishimoto, “Immuno-hyperthermia effected by antibody-conjugated nanoparticles selectively targets and eradicates individual cancer cells,” 2021, vol. 20, no. 13, pp. 1221–1230.
[18] X. Zhen, L. Jia, Q. Tang, Y. Zhao, P. Li, J. Li, X. Xie, and S. Wang, “Hybrid biointerface engineering nanoplatform for dual-targeted tumor hypoxia relief and enhanced photodynamic therapy,” J. Colloid Interface Sci., vol. 647, pp. 211–223, 2023.
[19] R. Cho, Y. Sakurai, H. S. Jones, H. Akita, A. Hisaka, and H. Hatakeyama, “Silencing of VEGFR2 by RGD-modified lipid nanoparticles enhanced the efficacy of anti-PD-1 antibody by accelerating vascular normalization and infiltration of T cells in tumors,” Cancers, vol. 12, 3630, 2020.
[20] X. Zhang and Z. He, “Cell membrane coated pH-responsive intelligent bionic delivery nanoplatform for active targeting in photothermal therapy,” Int. J. Nanomedicine, vol. 18, pp. 7729– 7744, 2023.
[21] D. Li, J. Xu, L. Kang, B. Zhao, J. Wang, and W. Xin, “Cell membrane-coated nanoparticles in disease therapy,” Chin. J. Biotechnol., vol. 40, no. 5, pp. 1323–1337, 2024.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
